

PATTERSON COMPANIES, INC.

Form 10-Q

December 04, 2014

[Table of Contents](#)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED October 25, 2014.**

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

**Commission File No. 0-20572**

**PATTERSON COMPANIES, INC.**

**(Exact name of registrant as specified in its charter)**

Minnesota  
(State of

41-0886515  
(I.R.S. Employer

incorporation)

Identification Number)

1031 Mendota Heights Road

St. Paul, Minnesota  
(Address of principal executive offices)

55120  
(Zip Code)

(651) 686-1600

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of November 26, 2014, there were 103,116,548 shares of Common Stock of the registrant issued and outstanding.

**Table of Contents****PATTERSON COMPANIES, INC.****INDEX**

	Page
<b><u>PART I - FINANCIAL INFORMATION</u></b>	
Item 1 - Financial Statements (Unaudited)	3-13
<u>Condensed Consolidated Balance Sheets as of October 25, 2014 and April 26, 2014</u>	3
<u>Condensed Consolidated Statements of Income and Comprehensive Income for the Three and Six Months Ended October 25, 2014 and October 26, 2013</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended October 25, 2014 and October 26, 2013</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6-13
<u>Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	14-17
<u>Item 3 - Quantitative and Qualitative Disclosures about Market Risk</u>	18
<u>Item 4 - Controls and Procedures</u>	18
<b><u>PART II - OTHER INFORMATION</u></b>	
<u>Item 5 - Unregistered Sales of Equity Securities and Use of Proceeds</u>	18
<u>Item 6 - Exhibits</u>	18
<u>Signatures</u>	19
<u>Exhibit Index</u>	20
<u>Safe Harbor Statement under The Private Securities Litigation Reform Act of 1995:</u>	

This Form 10-Q for the period ended October 25, 2014, contains certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which may be identified by the use of forward-looking terminology such as may, will, expect, anticipate, estimate, believe, goal, or continue, or comparable terminology that risks and uncertainties that are qualified in their entirety by cautionary language set forth herein under the caption

Factors That May Affect Future Operating Results, in our 2014 Annual Report on Form 10-K filed June 25, 2014 and other documents previously filed with the Securities and Exchange Commission.

Table of Contents**PART I FINANCIAL INFORMATION****PATTERSON COMPANIES, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS****(In thousands)**

	October 25, 2014 (Unaudited)	April 26, 2014
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 284,872	\$ 264,908
Short-term investments	57,850	40,775
Receivables, net	587,835	607,580
Inventory	499,893	436,463
Prepaid expenses and other current assets	59,276	65,991
Total current assets	1,489,726	1,415,717
Property and equipment, net	219,541	204,939
Long-term receivables, net	72,793	90,535
Goodwill	839,636	844,433
Identifiable intangibles, net	209,527	223,150
Other	26,226	85,903
Total assets	\$ 2,857,449	\$ 2,864,677
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 337,761	\$ 342,056
Accrued payroll expense	61,748	66,567
Other accrued expense	147,577	134,840
Total current liabilities	547,086	543,463
Long-term debt	725,000	725,000
Other	121,662	124,550
Total liabilities	1,393,748	1,393,013
Stockholders' equity:		
Common stock	1,029	1,040
Additional paid-in capital	2,615	
Accumulated other comprehensive income (loss)	(7,312)	25,370
Retained earnings	1,553,313	1,531,198
Unearned ESOP shares	(85,944)	(85,944)

Total stockholders' equity	1,463,701	1,471,664
Total liabilities and stockholders' equity	\$ 2,857,449	\$ 2,864,677

*See accompanying notes.*

**Table of Contents**

**PATTERSON COMPANIES, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
**AND COMPREHENSIVE INCOME**

(In thousands, except per share amounts)

(Unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>October 25, 2014</b>	<b>October 26, 2013</b>	<b>October 25, 2014</b>	<b>October 26, 2013</b>
Net sales	\$ 1,103,325	\$ 998,834	\$ 2,162,854	\$ 1,878,959
Cost of sales	797,503	709,403	1,560,807	1,308,010
Gross profit	305,822	289,431	602,047	570,949
Operating expenses	214,601	214,208	426,072	414,445
Operating income	91,221	75,223	175,975	156,504
Other income and expense:				
Other income, net	760	1,245	2,262	688
Interest expense	(8,544)	(8,777)	(17,312)	(17,344)
Income before taxes	83,437	67,691	160,925	139,848
Income taxes	29,659	25,663	56,858	51,928
Net income	\$ 53,778	\$ 42,028	\$ 104,067	\$ 87,920
Earnings per share:				
Basic	\$ 0.54	\$ 0.42	\$ 1.05	\$ 0.87
Diluted	\$ 0.54	\$ 0.41	\$ 1.04	\$ 0.86
Weighted average common shares:				
Basic	98,802	101,069	99,066	101,048
Diluted	99,376	101,968	99,779	101,944
Dividends declared per common share	\$ 0.20	\$ 0.16	\$ 0.40	\$ 0.32
Comprehensive income				
Net income	\$ 53,778	\$ 42,028	\$ 104,067	\$ 87,920
Foreign currency translation (loss) gain	(36,816)	14,699	(26,506)	6,394
Cash flow hedge loss	(3,867)	(48)	(6,176)	(97)

Comprehensive income	\$ 13,095	\$ 56,679	\$ 71,385	\$ 94,217
----------------------	-----------	-----------	-----------	-----------

*See accompanying notes.*

Table of Contents**PATTERSON COMPANIES, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In thousands)

(Unaudited)

	<b>Six Months Ended</b>	
	<b>October</b>	<b>October</b>
	<b>25,</b>	<b>26,</b>
	<b>2014</b>	<b>2013</b>
Operating activities:		
Net income	\$ 104,067	\$ 87,920
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	13,274	13,341
Amortization	11,410	9,700
Bad debt expense	1,153	1,362
Non-cash employee compensation	13,694	13,568
Excess tax benefits from stock-based compensation	(175)	(832)
Non-cash charges related to medical divestitures		5,114
Other changes from operating activities, net	(45,028)	(37,019)
Net cash provided by operating activities	98,395	93,154
Investing activities:		
Additions to property and equipment, net of acquisitions	(30,186)	(17,444)
Acquisitions and equity investments, net of cash		(140,963)
Proceeds from sale of assets	46,369	6,546
Other investing activities	(543)	(4,436)
Net cash provided by (used in) investing activities	15,640	(156,297)
Financing activities:		
Dividends paid	(40,174)	(48,388)
Repurchases of common stock	(47,539)	(22,199)
ESOP activity	(1,151)	(965)
Common stock issued, net	1,820	8,647
Payment on revolver	(130,000)	
Draw on revolver	130,000	135,000
Excess tax benefits from stock-based compensation	175	832
Net cash (used in) provided by financing activities	(86,869)	72,927
Effect of exchange rate changes on cash	(7,202)	1,046
Net increase in cash and cash equivalents	19,964	10,830
Cash and cash equivalents at beginning of period	264,908	505,228



Cash and cash equivalents at end of period	\$ 284,872	\$ 516,058
--	------------	------------

*See accompanying notes.*

Table of Contents

**PATTERSON COMPANIES, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

*(In thousands, except share and per share data)*

*(Unaudited)*

**October 25, 2014**

NOTE 1 GENERAL

*Basis of Presentation*

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of our Company as of October 25, 2014, and our results of operations and cash flows for the periods ended October 25, 2014 and October 26, 2013. Such adjustments are of a normal recurring nature. The results of operations for the periods ended October 25, 2014 and October 26, 2013, are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the financial statements included in the 2014 Annual Report on Form 10-K filed on June 25, 2014.

The condensed consolidated financial statements of Patterson Companies, Inc. ( *Patterson* or *Company* ) include the assets and liabilities of PDC Funding Company, LLC ( *PDC Funding* ) and PDC Funding Company II, LLC ( *PDC Funding II* ), wholly owned subsidiaries and separate legal entities under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities of our Company established to sell customer installment sale contracts to outside financial institutions in the normal course of business. The assets of PDC Funding and PDC Funding II would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding or PDC Funding II.

*Fiscal Year End*

The fiscal year end of our Company is the last Saturday in April. The second quarter of fiscal years 2015 and 2014 represents the 13 weeks ended October 25, 2014 and October 26, 2013, respectively. Fiscal years 2015 and 2014 each include 52 weeks of operations.

*Comprehensive Income*

Comprehensive income is computed as net income plus certain other items that are recorded directly to stockholders equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. The income tax benefit related to cash flow hedge losses was \$2,321 for the second quarter and \$7,134 for the six months ended October 25, 2014.

*Earnings Per Share*

The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted earnings per share (shares in thousands):

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>October 25, 2014</b>	<b>October 26, 2013</b>	<b>October 25, 2014</b>	<b>October 26, 2013</b>
<b>Denominator:</b>				
Denominator for basic earnings per share weighted average shares	98,802	101,069	99,066	101,048
Effect of dilutive securities stock options, restricted stock and stock purchase plans	574	899	713	896
Denominator for diluted earnings per share adjusted weighted average shares	99,376	101,968	99,779	101,944

**Table of Contents**

Options to purchase 124,000 shares of common stock during the three and six months ended October 25, 2014, and 75,000 shares during the three and six months ended October 26, 2013, respectively, were excluded from the calculation of diluted earnings per share because the effect would have been anti-dilutive. There were no unvested restricted stock awards excluded from the calculation of diluted earnings per share during the three and six months ended October 25, 2014, or the three and six months ended October 26, 2013, respectively, because the effect would have been anti-dilutive.

*Recently Issued Accounting Pronouncements*

In May 2014, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers. ASU No. 2014-09 supersedes the revenue recognition requirements in Revenue Recognition (Topic 605), and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. We are evaluating the new standard, but do not, at this time, anticipate a material impact to the financial statements once implemented.

**NOTE 2 ACQUISITIONS**

On August 16, 2013, Patterson Companies, Inc. completed the acquisition of all the outstanding stock of National Veterinary Services Limited ( NVS ) from Dechra Pharmaceuticals, PLC. NVS is the largest veterinary products distributor in the United Kingdom.

Operating results for this acquisition have been included in our Condensed Consolidated Statements of Income and Comprehensive Income from the date of acquisition and are reflected in the Veterinary reporting segment. The acquisition contributed \$173,946 of net sales to the segment for the second quarter and \$347,522 for the six months ended October 25, 2014. For the three and six months ended October 26, 2013, the acquisition contributed \$117,748 of net sales. Pro forma results are not presented, as the acquisition is not considered material to our Company.

**NOTE 3 GOODWILL AND OTHER INTANGIBLE ASSETS**

The goodwill balances and related activity by business segment as of April 26, 2014 and October 25, 2014 are as follows:

	<b>Balance at April 26, 2014</b>	<b>Acquisition Activity &amp; Divestitures</b>	<b>Translation And Other Activity</b>	<b>Balance at October 25, 2014</b>
Dental Supply	\$ 137,463	\$	\$ (210)	\$ 137,253
Rehabilitation Supply	545,007		(3,521)	541,486
Veterinary Supply	161,963		(1,066)	160,897
Total	\$ 844,433	\$	\$ (4,797)	\$ 839,636



**Table of Contents**

Balances of other intangible assets excluding goodwill are as follows:

	<b>October 25, 2014</b>	<b>April 26, 2014</b>
Unamortized indefinite lived:		
Copyrights, trade names and trademarks	\$ 76,464	\$ 76,464
Amortized:		
Distribution agreement, customer lists and other	283,177	286,365
Less: Accumulated amortization	(150,114)	(139,679)
Net amortized other intangible assets	133,063	146,686
Total identifiable intangible assets, net	\$ 209,527	\$ 223,150

**NOTE 4 DERIVATIVE FINANCIAL INSTRUMENTS**

Patterson is a party to certain offsetting and identical interest rate cap agreements. These cap agreements are not designated for hedge accounting treatment and were entered into to fulfill certain covenants of a sale agreement between a commercial paper conduit managed by The Bank of Tokyo-Mitsubishi UFJ, Ltd. and PDC Funding. On November 25, 2014, this agreement was amended on terms consistent with the expiring agreement. The cap agreements provide a credit enhancement feature for the financing contracts sold by PDC Funding to the commercial paper conduit.

The cap agreements are cancelled and new agreements entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts. As of October 25, 2014, PDC Funding had purchased an interest rate cap from a bank with a notional amount of \$500,000 and a maturity date of February 2022. Patterson Companies, Inc. sold an identical interest rate cap to the same bank.

Similar to the above agreements, PDC Funding II, and Patterson Companies, Inc. entered into offsetting and identical interest rate cap agreements with a notional amount of \$100,000 in fiscal 2014. In August 2014, these agreements were terminated and replaced with offsetting and identical interest rate cap agreements. The notional amount remained at \$100,000 and the new maturity date is October 2022.

In addition to the purchased and sold identical interest rate cap agreements described above, in May 2012 we entered into an interest rate swap agreement with a bank to economically hedge the interest rate risk associated with a portion of the finance contracts we had sold through the special purpose entities.

These interest rate contracts do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs.

In January 2014 we entered into a forward interest rate swap agreement with a notional amount of \$250,000 and accounted for as cash flow hedge, to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015 with a long-term loan for \$250,000 and a term of ten years.

The following presents the fair value of interest rate contracts included in the consolidated balance sheets:

Derivative type	Classification	October 25, 2014	April 26, 2014	October 26, 2013
<b>Assets:</b>				
Interest rate contracts	Other noncurrent assets	\$ 963	\$ 1,716	\$ 810
<b>Liabilities:</b>				
Interest rate contracts	Other noncurrent liabilities	\$ 964	\$ 1,720	\$ 820
Interest rate swaps	Other current liabilities	\$ 18,874	\$ 5,660	\$ 0

**Table of Contents**

The following table presents the effect of interest rate contracts on the consolidated statements of income and comprehensive income (net of tax):

Derivative type	Location of gain (loss) recognized on derivative	Three Months Ended		Six Months Ended	
		October 25, 2014	October 26, 2013	October 25, 2014	October 26, 2013
Interest rate contracts	Other income (expense), net	\$ 0	\$ 2	\$ 0	\$ 2
Interest rate swaps	Other comprehensive income	(\$ 3,867)	(\$ 48)	(\$ 6,176)	(\$ 97)

**NOTE 5 FAIR VALUE MEASUREMENTS**

Fair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used:

**Level 1** - Quoted prices in active markets for identical assets and liabilities at the measurement date.

**Level 2** - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

**Level 3** - Unobservable inputs for which there is little or no market data available. These inputs reflect management's assumptions of what market participants would use in pricing the asset or liability.

Our hierarchy for assets and liabilities measured at fair value on a recurring basis as of October 25, 2014 is as follows:

	Total	Quoted Prices in Active Markets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Assets:</b>				
Cash equivalents	\$ 44,648	\$ 44,648	\$	\$
Derivative instruments	963		963	
Total assets	\$ 45,611	\$ 44,648	\$ 963	\$
<b>Liabilities:</b>				
Derivative instruments	\$ 19,838	\$	\$ 19,838	\$



**Table of Contents**

Our hierarchy for assets and liabilities measured at fair value on a recurring basis as of April 26, 2014 is as follows:

	Total	Quoted Prices in Active Markets		
		(Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Assets:</b>				
Cash equivalents	\$ 51,511	\$ 51,511	\$	\$
Derivative instruments	1,716		1,716	
Total assets	\$ 53,227	\$ 51,511	\$ 1,716	\$
<b>Liabilities:</b>				
Derivative instruments	\$ 7,380	\$	\$ 7,380	\$

*Cash equivalents* We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months.

*Derivative instruments* Patterson's derivative instruments consist of interest rate contracts. These instruments are valued using observable inputs such as interest rates and credit spreads.

Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances, such as when there is evidence of impairment. There were no fair value adjustments to such assets during the periods ended October 25, 2014 or October 26, 2013.

Patterson's debt is not measured at fair value in the consolidated balance sheets. The estimated fair value of our debt as of October 25, 2014 and April 26, 2014 was \$744,144 and \$742,619, respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields. These are considered to be Level 2 inputs under the fair value measurements and disclosure guidance.

The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at October 25, 2014 and April 26, 2014.

**NOTE 6 SECURITIES**

On October 25, 2013 we invested in three time deposits with total principal of \$110,000 Canadian dollars. Our time deposit securities are classified as held-to-maturity securities as we have both the intent and ability to hold until maturity. They are carried at cost, adjusted for accrued interest and amortization. The current value is not materially different than fair value. The fair value was determined based on a discounted cash flow analysis using unobservable inputs (i.e. level 3 inputs), which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially lower fair value estimate. The interrelationship between these inputs is insignificant.

On October 24, 2014 time deposits with a principal value of \$45,000 Canadian matured with a value of \$45,436 Canadian. The proceeds were included in cash and cash equivalents at October 25, 2014. The remaining time deposits with a principal value of \$65,000 Canadian were classified as current assets at October 25, 2014 with a U.S. dollar

equivalent value of \$57,850.

NOTE 7 CUSTOMER FINANCING

As a convenience to our customers, we offer several different financing alternatives including both our Company-sponsored program and a third party program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under our sponsored program, equipment purchased by customers with strong credit may be financed up to a maximum of \$500 for any one customer. We generally sell the customers' financing contracts to outside financial institutions in the normal course of our business. Patterson currently has two arrangements under which we sell these contracts.

---

**Table of Contents**

Patterson operates under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with The Bank of Tokyo-Mitsubishi UFJ, Ltd. serving as the agent. We utilize a special purpose entity ( SPE ), PDC Funding, a consolidated, wholly owned subsidiary to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale. At least 9% of the proceeds are held by the conduit as security against eventual performance of the portfolio. The amount held by the conduit can be greater than 9% and is based upon certain ratios defined in the agreement. The capacity under the agreement at October 25, 2014 was \$500,000.

Patterson also maintains an agreement with Fifth Third Bank whereby the bank purchases customers financing contracts. Patterson has established another SPE, PDC Funding II, as a consolidated, wholly owned subsidiary, which sells financing contracts to the bank. We receive the proceeds of the contracts upon sale. At least 10% of the proceeds are held by the conduit as security against eventual performance of the portfolio. The amount held by the conduit can be greater than 10% and is based upon certain ratios defined in the agreement. The capacity under the agreement at October 25, 2014 was \$100,000.

The portion of the purchase price for the receivables held by the conduits is a deferred purchase price receivable, which is paid to the SPE as payments on the receivables are collected from customers. The deferred purchase price receivable represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The Company values the deferred purchase price receivable based on a discounted cash flow analysis using unobservable inputs (i.e. level 3 inputs), which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant increases in any of the significant unobservable inputs in isolation would not result in a materially lower fair value estimate. The interrelationship between these inputs is insignificant.

These financing arrangements are accounted for as a sale of assets under the provisions of ASC Topic No. 860, *Transfers and Servicing*. During the three and six months ended October 25, 2014, we sold \$47,059 and \$132,148, respectively, and during the three and six months ended October 26, 2013, we sold \$46,058 and \$115,554, respectively, of contracts under these arrangements. Patterson retains servicing responsibilities under both agreements, for which we are paid a servicing fee. The servicing fees received by Patterson are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded. The agreements require us to maintain a minimum current ratio and maximum leverage ratio. Patterson was in compliance with those covenants at October 25, 2014.

Included in cash and cash equivalents in the consolidated balance sheets are \$27,860 and \$28,152 as of October 25, 2014 and April 26, 2014, respectively, which represents cash collected from previously sold customer financing arrangements that have not yet been settled with the third party. Included in current receivables in the consolidated balance sheets are \$62,676, net of unearned income of \$1,730, and \$63,236, net of unearned income of \$5,894, as of October 25, 2014 and April 26, 2014, respectively, of finance contracts not yet sold by Patterson. A total of \$492,740 of finance contracts receivable sold under the agreements was outstanding at October 25, 2014. The deferred purchase price under the arrangements was \$68,113 and \$84,750 as of October 25, 2014 and April 26, 2014, respectively. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than one-percent of the loans originated.

**NOTE 8 SEGMENT REPORTING**

Patterson Companies, Inc. is comprised of three reportable segments: dental supply, veterinary supply, and rehabilitation supply. Our reportable business segments are strategic business units that offer similar products and services to different customer bases. The dental supply segment provides a virtually complete range of consumable

dental products, clinical and laboratory equipment and value-added services to dentists, dental laboratories, institutions and other dental healthcare providers throughout North America. The veterinary supply segment is a leading distributor of veterinary supplies, primarily to companion-pet (dogs, cats and other common household pets) and equine veterinary clinics. They also provide products and services used for the diagnosis, treatment and/or prevention of diseases in companion animals and equine throughout the United States and United Kingdom. The worldwide rehabilitation supply segment provides a comprehensive range of distributed and self-manufactured rehabilitation medical supplies and assistive products to acute care hospitals, long-term care facilities, rehabilitation clinics, dealers and schools.

**Table of Contents**

We evaluate segment performance based on operating income. The corporate office general and administrative expenses are included in the dental supply segment and consist of home office support costs in areas such as information technology, finance, human resources and facilities. If these corporate expenses were allocated to the segments, the results would not be materially different as the dental segment would absorb a significant portion of these expenses. The costs to operate the distribution centers are allocated to the operating units based on the through-put of each unit.

The following table presents information about Patterson's reportable segments:

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>October 25, 2014</b>	<b>October 26, 2013</b>	<b>October 25, 2014</b>	<b>October 26, 2013</b>
Net sales				
Dental supply	\$ 601,748	\$ 563,052	\$ 1,154,402	\$ 1,117,285
Veterinary supply	376,472	308,120	762,774	507,803
Rehabilitation supply	125,105	127,662	245,678	253,871
Consolidated net sales	\$ 1,103,325	\$ 998,834	\$ 2,162,854	\$ 1,878,959
Operating income				
Dental supply	\$ 59,008	\$ 53,174	\$ 112,221	\$ 108,664
Veterinary supply	14,336	12,151	28,323	21,198
Rehabilitation supply	17,877	9,898	35,431	26,642
Consolidated operating income	\$ 91,221	\$ 75,223	\$ 175,975	\$ 156,504

The following table presents sales information by product for all of Patterson's reportable segments:

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>October 25, 2014</b>	<b>October 26, 2013</b>	<b>October 25, 2014</b>	<b>October 26, 2013</b>
Consolidated				
Consumable and printed products *	\$ 790,840	\$ 714,643	\$ 1,587,617	\$ 1,324,592
Equipment and software *	228,572	205,569	408,001	401,712
Other	83,913	78,622	167,236	152,655
Total	\$ 1,103,325	\$ 998,834	\$ 2,162,854	\$ 1,878,959

\* Certain products were reclassified from equipment to consumables, to be consistent with the industry, in current and prior periods.

**NOTE 9 EMPLOYEE STOCK OWNERSHIP PLAN (ESOP)**

During 1990, our Board of Directors adopted a leveraged ESOP. In fiscal 2002 and 2006, under the provisions of the plan and related financing arrangements, Patterson loaned the ESOP \$12,612 (the 2002 note ) and \$105,000 (the 2006 note ), respectively. The contribution to the ESOP, and the resulting allocation to employees, is determined annually by the Board of Directors following the close of the fiscal year. Shares of stock acquired by the plan are allocated to each participant who has completed 1,000 hours of service during the plan year. These shares are accounted for under ASC 718-40, Share-based Payments *Employee Stock Ownership Plans*, and are not considered outstanding for computation of earnings per share until the shares are committed for release to the participants. We recognize expense based on the current fair value of the shares

**Table of Contents**

released to participants. As of October 25, 2014, a total of 2,736,969 of unallocated shares were held by the ESOP. The estimated ESOP expense recognized during the three months ended October 25, 2014 was \$3,000 and during the three months ended October 26, 2013 was \$5,700, respectively. The estimated ESOP expense recognized during the six months ended October 25, 2014 was \$6,000 and during the six months ended October 26, 2013 was \$11,400, respectively.

Table of Contents

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF  
FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

***OVERVIEW***

Our second quarter, fiscal 2015 financial information is summarized in this Management's Discussion and Analysis, and the Condensed Consolidated Financial Statements and related Notes. The following background is essential to fully understanding our Company's financial information.

Patterson operates a distribution business in three complementary markets: dental supply, veterinary supply and rehabilitation supply. Historically, our strategy for growth focused on internal growth and the acquisition of smaller distributors and businesses offering related products and services to the dental market. In fiscal 2002, we expanded our strategy to take advantage of a parallel growth opportunity in the veterinary supply market by acquiring the assets of J. A. Webster, Inc. on July 9, 2001. Effective January 1, 2013, Webster Veterinary Supply, Inc. changed its name to Patterson Veterinary Supply, Inc. Patterson added a third component to our business platform in fiscal 2004 when it entered the rehabilitation supply market with the acquisition of AbilityOne Products Corp. ( AbilityOne ) on September 12, 2003. AbilityOne is now known as Patterson Medical Holdings, Inc.

Operating margins of the veterinary business are considerably lower than the dental and rehabilitation supply businesses. While operating expenses run at a lower rate in the veterinary business, their gross margin is substantially lower due generally to pharmaceutical products sales, which have margins well below the average sundry product.

There are several important aspects of Patterson's business that are useful in analyzing it, including: (1) market growth in the various markets in which we operate; (2) internal growth; (3) growth through acquisition; and (4) continued focus on controlling costs and enhancing efficiency. Management defines internal growth as the increase in net sales from period to period, excluding the impact of changes in currency exchange rates, and excluding the net sales, for a period of twelve months following the transaction date, of businesses we have acquired.

**NVS Acquisition.** On August 16, 2013 Patterson Companies, Inc. completed the acquisition of all the outstanding stock of National Veterinary Services Limited ( NVS ) from Dechra Pharmaceuticals, PLC ( NVS Acquisition ). NVS is the largest veterinary products distributor in the United Kingdom. Total cash consideration paid for NVS was £88.7 million (approximately \$138.7 million). The acquisition is expected to be accretive to earnings by \$0.02 to \$0.03 per diluted share for the fiscal year ended April 25, 2015. The NVS business has lower gross margins and operating expenses than our historical businesses.

**Medical Restructuring.** On August 22, 2013 Patterson Companies, Inc. announced a plan to divest certain non-core product lines in its medical segment ( Medical Restructuring ). As a result of the plan to dispose of these product lines, the Company incurred a pre-tax restructuring charge of \$15 million or approximately \$0.13 per diluted share in fiscal year 2014. Approximately \$14 million of the restructuring charge related to non-cash losses on disposal of assets. The results for the second quarter of fiscal 2014 include charges of \$7 million, including non-cash losses on the sale of assets of \$5 million.



**Table of Contents****RESULTS OF OPERATIONS**

The following table sets forth, for the periods indicated, the percentage of net sales represented by certain operational data

	Three Months Ended		Six Months Ended	
	October 25, 2014	October 26, 2013	October 25, 2014	October 26, 2013
Net sales	100.0%	100.0%	100.0%	100.0%
Cost of sales	72.3%	71.0%	72.2%	69.6%
Gross margin	27.7%	29.0%	27.8%	30.4%
Operating expenses	19.5%	21.4%	19.7%	22.1%
Operating income	8.3%	7.6%	8.1%	8.3%
Other expense, net	(0.7%)	(0.8%)	(0.7%)	(0.9%)
Income before taxes	7.6%	6.8%	7.4%	7.4%
Net income	4.9%	4.2%	4.8%	4.7%

**QUARTER ENDED OCTOBER 25, 2014 COMPARED TO QUARTER ENDED OCTOBER 26, 2013.**

**Net Sales.** Consolidated net sales for the three months ended October 25, 2014 ( Current Quarter ) were \$1,103.3 million, a 10.5% increase from \$998.8 million for the three months ended October 26, 2013 ( Prior Quarter ). Acquisitions contributed 3.6% to Current Quarter sales growth, and foreign exchange rate changes had a favorable impact to Current Quarter sales growth of 0.2%.

Sales of the Dental segment were \$601.7 million, a 6.9% increase from \$563.0 million from the Prior Quarter. Current Quarter sales of consumables and printed office products increased 2.5%. Sales of dental equipment and software increased 15.6% to \$195.9 million, mainly due to increased sales from both basic equipment and technology products, led by new users of CEREC CAD/CAM systems. Sales of other services and products increased 6.9% in the Current Quarter.

Veterinary segment sales rose 22.2% to \$376.5 million. Acquisitions contributed 11.7% and foreign exchange rate changes contributed 1.5% to the current quarter sales growth. Excluding the NVS acquisition, consumables increased 7.4% due to the sales of new products, equipment and software sales were \$8.2 million, a decrease of 12.7%, and other services and products increased 4.3%.

Rehabilitation segment sales decreased 2.0% to \$125.1 million, due to reduced sales from the non-core product lines that were divested in the second and fourth quarters of fiscal year 2014 which accounted for a decrease of 4.2%, offset by a favorable impact of 0.4% from changes in foreign exchange rates.

**Gross Margins.** Consolidated gross margin decreased 130 basis points from the Prior Quarter to 27.7%. The NVS Acquisition accounts for 100 basis points of the decrease and the Medical Restructuring accounts for a 10 basis points increase, resulting in a comparable decrease of 40 basis points from Prior Quarter. The 40 basis point decrease is

predominantly the result of the mix between product lines.

**Operating Expenses.** The consolidated operating expense ratio of 19.5% decreased 190 basis points from Prior Quarter at 21.4%. The NVS Acquisition accounts for 60 basis points of the decrease and the Medical Restructuring also accounts for 60 basis points of the decrease. This results in a comparable operating expense ratio of 22.5% versus 23.2% in the Prior Quarter, a decrease of 70 basis points.

**Operating Income.** Current Quarter operating income was \$91.2 million, or 8.3% of net sales. In the Prior Quarter, operating income was \$75.2 million, or 7.6% of net sales. The Medical Restructuring and the NVS Acquisition affected operating margins in both quarters. The comparable operating margin rate is 9.3% in the Current Quarter and 9.0% in the Prior Quarter.

---

**Table of Contents**

**Other (Expense) Income, Net.** Net other expense was \$7.8 million in the Current Quarter compared to \$7.5 million in the Prior Quarter. Net other expense is comprised primarily of interest expense, partly offset by interest income.

**Income Tax Expense.** The effective income tax rate for the Current Quarter was 35.5% compared to 37.9% in the Prior Quarter. The decrease in the Current Quarter rate is due primarily to the Prior Quarter Medical Restructuring and the geographical shift in profits between domestic and international for the Current Quarter. For the fiscal year, the income tax rate from recurring operations is expected to be in a range from 34.7% to 35.2%.

**Net Income and Earnings Per Share.** Net income was \$53.8 million, compared to \$42.0 million in the Prior Quarter. Earnings per diluted share was \$0.54 in the Current Quarter compared to \$0.41 in the Prior Quarter. The Prior Quarter earnings per share after adding back the \$0.07 per share impact from the Medical Restructuring was \$0.48. Diluted shares outstanding in the Current Quarter were 99,376,000 compared to 101,968,000 in the Prior Quarter. The decrease in the share count is due to share repurchase activity over the past year. The Current Quarter's cash dividend was \$0.20 per common share compared to \$0.16 in the Prior Quarter.

***SIX MONTHS ENDED OCTOBER 25, 2014 COMPARED TO SIX MONTHS ENDED OCTOBER 26, 2013.***

**Net Sales.** Consolidated net sales increased 15.1% for the six months ended October 25, 2014 ( Current Period ) and totaled \$2,162.9 million compared to \$1,879.0 million for the six months ended October 26, 2013 ( Prior Period ). Sales included a contribution from acquisitions of 11.2% and a positive impact from foreign currency translation rates of 0.2%.

Dental segment sales of \$1,154.4 million were 3.3% higher than the \$1,117.3 million in the Prior Period. Consumable sales increased 2.2% from the Prior Period. Equipment and software sales increased 4.0%. Sales of other services and products increased 7.1% in the Current Period.

Sales of the Veterinary segment rose 50.2% to \$762.8 million in the Current Period, mainly due to a 41.3% growth from acquisitions. Excluding the NVS acquisitions, consumables increased 7.3%, equipment and software sales decreased 10.8% and other increased 8.1%.

Rehabilitation segment sales decreased 3.2% to \$245.7 million, due to reduced sales from the non-core product lines that were divested in the second and fourth quarters of fiscal 2014 which accounted for a decrease of 5.0%, offset by a favorable impact of 0.9% from changes in foreign exchange rates.

**Gross Margins.** Consolidated gross margin decreased 260 basis points from the Prior Period to 27.8%. The NVS Acquisition accounts for 260 basis points of the decrease and the Medical Restructuring accounts for a 10 basis points increase, resulting in a comparable decrease of 10 basis points from the Prior Period.

**Operating Expenses.** The consolidated operating expense ratio decreased 240 basis points from the Prior Period to 19.7%. The NVS Acquisition accounts for 190 basis points of the decrease and the Medical Restructuring accounts for 30 basis points of the decrease. This brings our adjusted operating expense ratio to 22.8% for the Current Period versus 23.0% in the Prior Period.

**Operating Income.** Current Period operating income was \$176.0 million, or 8.1% of net sales. In the Prior Period, operating income was \$156.5 million, or 8.3% of net sales. The decrease in the operating margin is due to the impacts from the NVS Acquisition and the Medical Restructuring. The comparable operating margin ratio for the Current Period is 9.2% versus 9.1% in the Prior Period.

**Other (Expense) Income, Net.** Net other expense was \$15.0 million in the Current Period compared to \$16.7 million in the Prior Period. Net other expense is comprised primarily of interest expense, partly offset by interest income. Interest income of \$2.6 million was up from \$2.3 million in the Prior Period.

**Income Tax Expense.** The effective income tax rate for the Current Period was 35.3% compared to 37.1% in the Prior Period. The decrease in the current year rate is due primarily to the Medical Restructuring and the geographical shift in profits between domestic and international for the period.

---

**Table of Contents**

**Net Income and Earnings Per Share.** Net income was \$104.1 million, compared to \$87.9 million in the Prior Period. Earnings per diluted share was \$1.04 in the Current Period compared to \$0.86 in the Prior Period. The Prior Period earnings per share after adding back the \$0.07 per share impact from the Medical Restructuring was \$0.93. Diluted shares outstanding in the Current Period were 99,779,000 compared to 101,944,000 in the Prior Period. The decrease in the share count is due to share repurchase activity over the past year. The Current Period's cash dividend was \$0.40 per common share compared to \$0.32 in the Prior Period.

***LIQUIDITY AND CAPITAL RESOURCES***

Our cash flows from operations in the six-months ended October 25, 2014 were \$98.4 million compared to \$93.2 million in the Prior Period. The increase is primarily a result of increased net income, partially offset by the timing and magnitude of income tax and accounts payables disbursements.

Net cash provided by investing activities was \$15.6 million in the Current Period compared to a use of \$156.3 million in the Prior Period. The Current Period included the maturing of a time deposit investment with a value of approximately \$40.4 million. The Prior Period included the acquisition of NVS for approximately \$138.7 million. We expect to use a total of approximately \$50 million for capital expenditures in fiscal 2015, with our main investment in information systems.

Cash used in financing activities during the Current Period was \$86.9 million, which included \$40.2 million for dividend payments and \$47.5 million for stock repurchases. In the Prior Period, cash provided by financing activities was \$72.9 million including \$135 million for a draw on our revolver for the purchase of NVS, offset by dividend payments of \$48.4 million and stock repurchases of \$22.2 million.

In fiscal 2014, we invested in three time deposits with total principal of \$110 million Canadian dollars. On October 24, 2014, time deposits with a principal value of \$45 million Canadian matured with a value of \$45.4 million Canadian (U.S. equivalent value of \$40.4 million). The proceeds were included in cash and cash equivalents at October 25, 2014. The remaining time deposits with a principal value of \$65 million Canadian were classified as current assets at October 25, 2014 with a U.S. dollar equivalent value of \$57.9 million.

We have a \$250 million note due in the fourth quarter of fiscal year 2015. We have both the intent and ability to refinance at that time; therefore we have classified this balance as long term debt on the balance sheet as of October 25, 2014.

We expect funds generated from operations, existing cash balances and credit availability under existing debt facilities will be sufficient to meet our working capital needs and to finance anticipated expansion plans and strategic initiatives over the remainder of fiscal 2015.

As of October 25, 2014, \$300 million was available under our \$300 million revolving credit facility. Our current credit agreement expires in fiscal 2017.

***CRITICAL ACCOUNTING POLICIES AND ESTIMATES***

In May 2014, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers. ASU No. 2014-09 supersedes the revenue recognition requirements in Revenue Recognition (Topic 605), and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting

periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. We are evaluating the new standard, but do not, at this time, anticipate a material impact to the financial statements once implemented.

**Table of Contents*****FACTORS THAT MAY AFFECT FUTURE OPERATING RESULTS***

In our Form 10-K for the year ended April 26, 2014, we described material risk factors facing our business. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. As of the date of this report, there have been no material changes to the risk factors described in our Form 10-K.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes since April 26, 2014 in our market risk. For further information on market risk, refer to Item 7A in our 2014 Annual Report on Form 10-K filed June 25, 2014.

**ITEM 4. CONTROLS AND PROCEDURES**

Under the supervision and with the participation of our Company's management, including our Company's President and Chief Executive Officer ( CEO ) and its Chief Financial Officer ( CFO ), management evaluated the effectiveness of the design and operation of our Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of October 25, 2014. Based upon their evaluation of these disclosure controls and procedures, the CEO and CFO concluded that the disclosure controls and procedures were effective as of October 25, 2014.

There were no changes in our Company's internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act) that occurred during the quarter ended October 25, 2014 that have materially affected, or are reasonably likely to materially affect, our Company's internal control over financial reporting.

**PART II OTHER INFORMATION****ITEM 5. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On March 19, 2013, Patterson's Board of Directors approved a new share repurchase plan that replaced the existing share repurchase plan. Under the new plan, up to 25 million shares may be purchased in open market transactions through March 19, 2018. As of October 25, 2014, a total of 20,851,993 shares remain available under the current repurchase authorization.

The following table presents activity under the stock repurchase program during the second quarter of fiscal 2015 ended October 25, 2014.

			<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Maximum Number of Shares That May Be Purchased Under the Plan</b>
	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid per Share</b>		

Edgar Filing: PATTERSON COMPANIES, INC. - Form 10-Q

July 27, 2014 to August 23, 2014	65,000	\$ 40.56	65,000	20,876,993
August 24, 2014 to September 20, 2014	25,000	\$ 40.88	25,000	20,851,993
September 21, 2014 to October 25, 2014				20,851,993
	90,000	\$ 40.65	90,000	

**ITEM 6. EXHIBITS**

The exhibits listed in the accompanying exhibit index are filed as part of this Quarterly Report on Form 10-Q.

All other items under Part II have been omitted because they are inapplicable or the answers are negative, or were previously reported in the 2014 Annual Report on Form 10-K filed June 25, 2014.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**PATTERSON COMPANIES, INC.**  
(Registrant)

Dated: December 4, 2014

By: /s/ Ann B. Gugino  
Ann B. Gugino  
Vice President, Chief Financial Officer and Treasurer  
(Principal Financial Officer and Principal Accounting  
Officer)

**Table of Contents**

**EXHIBIT INDEX**

**Exhibit**

**Number**

**Exhibit Description**

31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a), under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101	Financials in XBRL format